1300645-77-5

Basic information

• Product Name: 3,4-dimethoxy-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxymethyl]-pyridine
• Synonyms: 3,4-dimethoxy-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxymethyl]-pyridine
• CAS NO: 1300645-77-5
• Molecular Weight: 371.241
• Mol File: 1300645-77-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3,4-dimethoxy-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxymethyl]-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dimethoxy-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxymethyl]-pyridine(1300645-77-5)
• EPA Substance Registry System: 3,4-dimethoxy-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxymethyl]-pyridine(1300645-77-5)

Safety Data

• Hazardous Substances Data: 1300645-77-5(Hazardous Substances Data)

Upstream product

• 72830-08-1 2-hydroxymethyl-3,4-dimethoxypyridine 
• 72830-09-2 2-Chloromethyl-3,4-dimethoxy-pyridine; hydrochloride 
• 269409-70-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 

Downstream Products

• 1300645-60-6 4-(2-[4-(3,4-dimethoxypyridin-2-yl)methoxyphenyl]pyridin-3-yl)morpholine 

Relevant articles and documents

ARYL AMINOPYRIDINE PDE10 INHIBITORS

The present invention is directed to aryl aminopyridine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.